[Metastatic renal cell carcinoma: pretherapeutic approach before antiangiogenic treatment. A case report].
Antiangiogenic treatment initiation justifies a clinical and biological pretherapeutic assessment and a close follow-up of side effects according to each drug. Because of potential healing complications, a deadline of 4 weeks after surgery is recommended before starting antiangiogenic treatment. The optimal sequence and the potential role of neo-adjuvant therapies remain to define. In the absence of prospective data, nephrectomy is still recommended in renal cell carcinoma management.
Méjean
A
A
Service d'Urologie, Hôpital Necker, rue de Sèvres, Paris cedex 15, France.
Guy
L
L
Jacqmin
D
D
Joly
F
F
Négrier
S
S
Pignot
G
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D007372:Interferons